VeriStrat and Epidermal Growth Factor Receptor Mutation Status Study Results Presented at 16th World Conference On Lung Cancer
VeriStrat and Epidermal Growth Factor Receptor Mutation Status Study results presented at 16th World Conference on Lung Cancer
Biodesix named to Inc. 500|5000 Fastest-Growing Private Companies list
Biodesix Adds Biognosys’ Proteomics Technology To Its Diagnostic Development Capabilities; Collaboration Enables Protein Identification Within Proteomic Signatures
Biodesix recently added Biognosys' Proteomics to their capabiltites.
HealthNet now covers Biodesix' VeriStrat test
Biodesix raises follow-on series E financing
Biodesix announced that the VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation.
Biodesix' VeriStrat test is covered by Cigna
Biodesix' VeriStrat test has won approval from CareFirst BlueCross BlueShield
Lung Cancer Journal: VeriStrat Proteomic Test Improves Overall Survival and Decreases Medical Costs for Patients with Advanced NSCLC
The paper’s authors conclude that using VeriStrat improves overall survival and decreases medical costs in the US payer system.
Biodesix And Inivata To Investigate Clinical Utility Of Next Generation Sequencing-Blood Based Tests For Patients With Advanced Lung Cancer
Biodesix, Inc and Inivata announced a partnership today to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for lung cancer.